Conjugate Vaccine Global Market Report 2024

The conjugate vaccine market has grown rapidly in recent years. It will grow from $16.77 billion in 2023 to $19.11 billion in 2024 at a compound annual growth rate (CAGR) of 13.9%. The expansion observed in the historical period can be attributed to several factors, including the burden of diseases, government-driven immunization programs, heightened awareness regarding vaccination, a focus on pediatric vaccination, and the prevailing trends in preventive healthcare.

The conjugate vaccine market is expected to see rapid growth in the next few years. It will grow to $30.65 billion in 2028 at a compound annual growth rate (CAGR) of 12.5%. The anticipated growth in the forecasted period can be attributed to a range of factors, including the expansion of immunization policies, the dynamics of an aging population, the emergence of new vaccine indications, heightened global health security concerns, international collaboration efforts, and the impact of economic development. Noteworthy trends expected in this period include increased collaborations and partnerships for efficient vaccine distribution, tailored approaches targeting high-risk populations, the application of vaccines in emerging infectious diseases, advancements in vaccine manufacturing technologies, and global health initiatives focused on achieving vaccine equity.

The anticipated growth in the conjugate vaccine market is driven by the increasing utilization of these vaccines among adults. Conjugate vaccines are specifically formulated to elicit a robust immune response against bacterial capsular polysaccharides, fortifying the body's defenses against bacterial infections. Their application in the adult population serves to mitigate the risk of severe illness, complications, and the transmission of bacterial diseases by bolstering the immune response. As evidenced by the Historical National Influenza Vaccination Coverage report spanning 2020-2022 from the National Centre for Immunization Research and Surveillance, vaccination coverage for the 15 - < 50 years age group reached 29.5% at the end of 2022, showcasing a notable increase from the 22.8% recorded in 2021. This upsurge in the use of conjugate vaccines for adults is a significant driver of the growth in the conjugate vaccine market.

The projected expansion of the conjugate vaccine market is underpinned by the rising incidence of infectious diseases. Infectious diseases, caused by pathogenic microorganisms such as bacteria, viruses, parasites, or fungi, pose significant public health challenges. Conjugate vaccines play a pivotal role in preventing infectious diseases, particularly those caused by specific bacteria, and are especially crucial for vulnerable populations such as infants and young children. According to the Pan American Health Organization's data from October 2022, approximately 10.6 million individuals contracted tuberculosis (TB) in 2021, marking a 4.5% increase from 2020. Among those affected, 1.6 million individuals succumbed to TB, including 187,000 cases among people living with HIV. This escalating incidence of infectious diseases is a key factor propelling the growth of the conjugate vaccine market.

Innovation in conjugate vaccines emerges as a prominent trend gaining traction in the conjugate vaccine market. Companies actively involved in this market are strategically focused on the development of innovative conjugate vaccines to maintain their competitive standing. An exemplar of this trend is Pfizer Inc., a US-based pharmaceutical and biotechnology company, which, in June 2022, launched Prevnar 20, a pneumococcal 20-valent conjugate vaccine, in Canada. This vaccine is designed to prevent pneumonia and invasive pneumococcal infections in adults aged 18 and older. Prevnar 20 includes conjugates for the 13 serotypes covered by PREVNAR 13, along with conjugates for seven additional serotypes associated with invasive pneumococcal disease, characterized by high case-fatality rates, antibiotic resistance, and meningitis.

Major companies operating in the conjugate vaccine market are directing their efforts towards the development of advanced conjugate vaccines, including the 21-valent pneumococcal conjugate vaccine. This type of vaccine is crafted to provide protection against infections caused by Streptococcus pneumoniae bacteria. An illustrative example is Merck & Co., Inc., a US-based pharmaceutical company, which, in April 2022, received the Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for its 'V116.' V116 is a 21-valent pneumococcal conjugate vaccine designed for the prevention of invasive pneumococcal disease (IPD) and pneumococcal pneumonia. Tailored to target strains of pneumococcal bacteria commonly found in adults, V116 represents a significant advancement in conjugate vaccine development.

In August 2022, GSK, a UK-based pharmaceutical and biotechnology company, completed the acquisition of Affinivax Inc. for $2.1 billion. This strategic move by GSK is aimed at fortifying its portfolio of specialty medicines and vaccines, particularly in the realm of advanced pneumococcal vaccines. The acquisition includes Affinivax's AFX3772, contributing to GSK's position in the development of cutting-edge conjugate vaccines. Affinivax, a US-based biotechnology company, specializes in the development of conjugate vaccines.

Major companies operating in the conjugate vaccine market report are Sanofi S.A., Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Bharat Biotech International Limited, Serum Institute of India Private Limited, Biological E. Limited, Bavarian Nordic A/S, CSL Limited, Novartis AG, GreenSignal Bio Pharma Limited, Taj Pharmaceuticals Limited, Vaxcyte Inc., Neuron Biotech Co. Ltd., Bio-Med Pvt. Ltd., AstraZeneca plc, Johnson & Johnson, Moderna Inc., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, Valneva SE, Dynavax Technologies Corporation, Emergent BioSolutions Inc., Hualan Biological Engineering Inc., Inovio Pharmaceuticals Inc., Medicago Inc., Mitsubishi Tanabe Pharma Corporation, Panacea Biotec Ltd., Protein Sciences Corporation, Seqirus.

North America was the largest region in the global conjugate vaccine market in 2023. The regions covered in the conjugate vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the conjugate vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Two primary types of conjugate vaccines are monovalent conjugate vaccines and multivalent conjugate vaccines. Monovalent conjugate vaccines consist of a single conjugated antigen, typically designed to target a specific pathogen or strain. These vaccines are utilized for preventing infections caused by bacteria with a polysaccharide capsule, such as streptococcus pneumoniae, haemophilus influenzae type B, and neisseria meningitidis. Monovalent conjugate vaccines are developed to address various diseases, including pneumococcal, influenza, meningococcal, and typhoid. They find application in pediatric and adult patient populations and are utilized in diverse healthcare settings such as hospitals, clinics, homecare, and other medical facilities.

The conjugate vaccine research report provides conjugate vaccine market statistics, including the conjugate vaccine industry's global market size, regional shares, competitors with a conjugate vaccine market share, detailed conjugate vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the conjugate vaccine industry. This conjugate vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The conjugate vaccine market consists of sales of diphtheria, tetanus, and pertussis (DTaP) conjugate vaccine, haemophilus influenza type b (Hib) conjugate vaccine, and E. coli conjugate vaccine. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.